ZYMEWORKS DL-00001
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. … Read more
ZYMEWORKS DL-00001 (ZA8) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ZYMEWORKS DL-00001 (ZA8) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ZYMEWORKS DL-00001 - Net Assets Trend (None–None)
This chart illustrates how ZYMEWORKS DL-00001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ZYMEWORKS DL-00001 (None–None)
The table below shows the annual net assets of ZYMEWORKS DL-00001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ZYMEWORKS DL-00001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ZYMEWORKS DL-00001 Competitors by Market Cap
The table below lists competitors of ZYMEWORKS DL-00001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sunstone Development Co Ltd
SHG:603612
|
$1.52 Billion |
|
Zhuzhou Kibing Group Co Ltd
SHG:601636
|
$1.53 Billion |
|
FinVolution Group
NYSE:FINV
|
$1.53 Billion |
|
BSP Financial Group Ltd
AU:BFL
|
$1.53 Billion |
|
Red Avenue New Materials Group Co Ltd
SHG:603650
|
$1.52 Billion |
|
Harbour Energy plc
PINK:PMOIF
|
$1.52 Billion |
|
China Great Wall Securities Co Ltd Class A
SHE:002939
|
$1.52 Billion |
|
CNNC Hua Yuan Titanium Dioxide Co Ltd
SHE:002145
|
$1.52 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ZYMEWORKS DL-00001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ZYMEWORKS DL-00001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ZYMEWORKS DL-00001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ZYMEWORKS DL-00001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ZYMEWORKS DL-00001 (ZA8) | €- | N/A | N/A | $1.52 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |